
Blockbuster weight loss and diabetes drugs may lower patients’ risk of developing some common types of cancer that are closely linked to obesity, new evidence suggests. Patients with Type 2 diabetes who were prescribed drugs known as glucagon-like peptide-1, or GLP-1, developed fewer obesity-related cancers than patients who were treated with insulin, according to a study published Friday in …
Subscribe to continue reading this article.
Already subscribed? To login in, click here.
Originally Published: